Niccolò Riccardi Filippo Del Puente Lucia Taramasso Antonio Di Biagio
10.1177/2325958218821657
J Int Assoc Provid AIDS Care
2019 Jan-Dec;18:2325958218821657.
dolutegravir dual-therapy optimization rilpivirine
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/30798670/
Anti-HIV Agents / therapeutic use Drug Substitution HIV Infections / drug therapy Sustained Virologic Response Viral Load / drug effects
Anti-HIV Agents / therapeutic use Drug Substitution HIV Infections / drug therapy Sustained Virologic Response Viral Load / drug effects Case Reports Observational Study Adult Aged Drug Therapy, Combination Female HIV-1 / drug effects HIV-1 / genetics Heterocyclic Compounds, 3-Ring / therapeutic use Humans Male Middle Aged Mutation Nitriles Oxazines Piperazines Pyridazines / therapeutic use Pyridones Pyrimidines Raltegravir Potassium / therapeutic use Rilpivirine / therapeutic use Anti-HIV Agents Heterocyclic Compounds, 3-Ring Nitriles Oxazines Piperazines Pyridazines Pyridones Pyrimidines etravirine Raltegravir Potassium dolutegravir Rilpivirine
PMC6748463
30798670
Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
2019